|
24 |
25 |
26 |
9:00-
10:25 |
Opening Ceremony and Keynote Forum |
Session 1-4: Nanosensors, Microarray, Biochips and Cytokine Antibody Arrays |
Session 1-10: Nanotechnology and Drug Delivery Technologies of Antibodies |
10:40-
12:00 |
Session 1-5: Generation of Immune and Synthetic Libraries, and High Throughput Screening |
Session 1-11: Phage and Ribosome Display Technologies |
9:00-
10:25 |
Session 1-6: Antibody Conjugates, Antibody Fragments and Novel Adaptors and Molecular Scaffolds |
Sesssion 1-12: Nanobodies, BiTEs and TandAbs |
10:40-
12:00 |
Session 2-3: Receptor Signaling Protein Tyrosine Phosphatase (PTP) Targets |
Session 2-7: Chaperone, Cofactor Binding and Complement Targets |
9:00-
10:25 |
Session 2-4: Receptor Tyrosine Kinase (RTK) Targets |
Session 2-8: RNA-directed DNA polymerase and DNA Topoisomerase Targets |
10:40-
12:00 |
Session 2-13: MHC Class I Receptor Targets |
Session 2-17: Translation Regulator and Transporter Targets |
9:00-
10:25 |
Session 2-14: Peptide Hormone and Hormone Targets |
Session 2-18: Antibody Drugs Targeting Other Signaling Pathway Mediates |
10:40-
12:00 |
Session 3-1B: Antibodies Targeting Breast Cancer -Signaling Pathways II |
Session 3-1D: Successful Industrial Case Studies of Therapeutic Monoclonal Antibodies against Breast Cancer
-Industrial and Clinical Symposium |
9:00-
10:25 |
Session 3-4A: Targeting Thyroid Cancer |
Session 3-8A: Targeting Colorectal and Colon Cancers |
Session 3-4B: Pipeline Analysis-MAbs on Thyroid Cancer
-Industrial and Clinical Symposium |
Session 3-8B: Case Studies on MAbs for Colorectal and Colon Cancers
-Industrial and Clinical Symposium |
9:00-
10:25 |
Session 3-5A: Antibodies for Ovarian, Endometrial, Fallopian Tube and Cervical Cancers
|
Session 3-9A: Targeting Head, Nasopharyngeal, Neck and Brain Cancers |
Session 3-9B: Case Studies on MAbs for Head, Nasopharyngeal, Neck and Brain Cancers
-Industrial and Clinical Symposium |
10:40-
12:00 |
Session 4-2: Antibodies against HIV/AIDS |
Session 4-4: Therapeutic Antibodies for Anti Severe Bacterial and Parasite Infection and STDs |
9:00-
10:25 |
Session 5-2: Anti-Alzheimer's Monoclonal Antibodies |
Session 5-4: Antibodies for Psychotics and Depression: Bipolar, Schizophrenia and Depression |
10:40-
12:00 |
Session 6-2: MAbs against Rheumatoid Arthritis, Spondylitis Ankylosans and Inflammatory Bowel Disease |
Session 6-4: Antibody Therapy in Solid Organ Transplantation -Renal/ Kidney, Liver, Heart and Lung, and Pancreas |
9:00-
10:25 |
Session 7-2: Mabs against Crohn’s disease, and other server G.I. Disorders
|
Session 7-4: Mabs against Endocrine, Metabolic and Genetic Disorders |
10:40-
12:00 |
Session 8-2: The Chemistry of Targeted Drug Discovery |
Session 8-4: New Antibody Therapies With Strong Efficacy And Good Side Effect Profiles
|
9:00-
12:00 |
Session 9-2: Monoclonal antibodies for Diagnosis of Cancers
|
Session 9-5: Antibodies for Inflammatory Disease Diagnostics |
9:00-
10:25 |
Session 9-3: Antibodies for HIV/AIDS and Major Severe Infectious Disease Testing
|
Session 3-10A: Targeting Rectum, Liver, Cholecyst and Pancreatic Cancers |
Session 3-10B: Case Studies on MAbs for Rectum, Liver, Cholecyst and Pancreatic Cancers
-Industrial and Clinical Symposium |
10:40-
12:00 |
Session 10-2: Bioprocess Development For Production Modification Of Mabs |
Session 10-4: Biologics & Biosimilars of Launched Therapeutics |
10:40-
12:00 |
Session 11-2: Case Studies: Strategic Alliances and Improvement on Existing Partnerships |
Session 11-4: Biotech and Pharmaceutical Licensing and Deal-Making on mAB |
12:15-
13:00 |
Lunch |
Lunch |
Lunch |
13:30-
15:10 |
Session 1-1: Immunology, Immunogenicity, Cell and Molecular Biology |
Session 1-7: Humanization Technology of Antibodies |
Session 1-13: ADC, Immunogen's TAP System, and Aptamers |
15:30-
17:10 |
Session 1-2: Genetics, Proteomics, Epitomics, System Biology for Antibody Discovery |
Session 1-8: Recombinant DNA Biotechnology in Antibody Industries |
Session 1-14: Antibody Imaging, Labeled Antibodies and Radioimmunotherapy |
13:30-
15:10 |
Session 1-3: Hybridoma Technology and Antibody Gene Manipulation |
Session 1-9: Antibody Characterization Technologies |
Session 15: Transgenic Animals and Plants |
13:30-
15:10 |
Session 2-1: Oxidoreductase, Carboxypeptidase, Metallopeptidase & Hydrolase Targets |
Session 2-5: Cytokine and Chemokine Targets |
Session 2-9: Extracellular Matrix Structural Constituent Targets |
15:30-
17:10 |
Session 2-2: Protease, Serine-type Peptidase and Protesome Targets |
Session 2-6: Cell Adhesion Molecule Targets |
Session 2-10: Growth Factor Targets |
13:30-
15:10 |
Session 2-11: B and T Cell Receptor Targets |
Session 2-15: Intracellular Ligand-gated Ion Channel Targets |
Session 2-19: Antibodies Targeting Cancer Stem Cells |
15:30-
17:10 |
Session 2-12: Transmembrane and G-protein Coupled Receptor Targets |
Session 2-16: Receptor Signaling Complex Scaffold Targets |
Session2- 20: Targets of Antibody Conjugates |
15:30-
17:10 |
Session 3-1A: Antibodies Targeting Breast Cancer Signaling Pathways I |
Session 3-1C: Antibodies Targeting Breast Cancer Receptors and Cells |
Session 3-11A: Targeting Lymphoma, Melanoma, Sarcomas and Skin Cancers |
Session 3-11B: Case Studies on MAbs for Lymphoma, Melanoma, Sarcomas and Skin Cancers
-Industrial and Clinical Symposium |
13:30-
15:10 |
Session 3-2A: Antibodies Targeting Lung Cancers |
Session 3-6A: Targeting Hematologic Cancers, Leukemia and Myelodysplasia, non-Hodgkin's Lymphoma |
Session 3-12A: Targeting Chest, Bone, and Soft Tissue Cancers |
Session 3-2B: Pipeline Analysis-MAbs on Lung Cancer
-Industrial and Clinical Symposium |
Session 3-6B: Case Studies of MAbs- Hematologic Cancers, Leukemia and Myelodysplasia, non-Hodgkin's Lymphoma
-Industrial and Clinical Symposium |
Session 3-12B: Case Studies on MAbs for Chest, Bone, and Soft Tissue Cancers
-Industrial and Clinical Symposium |
15:30-
17:10 |
Session 3-3A: Antibodies Targeting Prostate Cancers |
Session 3-7A: Targeting Oesophageal, Esophageal, Peritoneal and Gastrointestinal Cancers |
Session 3-13A: Targeting Urology, Bladder, Kidney and Pediatric Cancers |
Session 3-3B: Pipeline Analysis-MAbs on Prostate Cancer
-Industrial and Clinical Symposium |
Session 3-7B: Industrial Pipeline Analysis on MAbs for Oesophageal, Esophageal, Peritoneal and Gastrointestinal Cancers
-Industrial and Clinical Symposium |
Session 3-13B: Case Studies on MAbs for Urology, Bladder, Kidney and Pediatric Cancers
-Industrial and Clinical Symposium |
13:30-
15:10 |
Session 4-1: Antibody-Mediated Immunity and Infections
|
Session 4-3: Antibodies against HBV/ HCV
|
Session 4-5: Therapeutic Antibodies for other Severe Viral Infections |
Session 4-7: Case Studies on Therapeutic MAbs for Infection Diseases
-Industrial and Clinical Symposium |
Session 4-6: Therapeutic Antibodies for Systematic Fungal Infections |
15:30-
17:10 |
Session 5-1: Neuroimmunology and Antibody Development |
Session 5-3: MAbs for Parkinson and Epilepsy Diseases |
Session 5-5: Monoclonal Antibodies on Multiple Sclerosis, Anxiety and Attention Disorders
|
Session 5-6: Case Studies on Therapeutic NeuroMAbs for CNS Diseases
-Industrial and Clinical Symposium |
13:30-
15:10 |
Session 6-1: MAbs Targeting Cytokine Receptors Mediated Inflammation |
Session 6-3: MAbs against Respiratory Disorders and Severe Asthma
|
Session 6-5: MAbs against Psoriasis, Systemic Lupus Erythematosus (SLE) and Sjogren's Syndrome
|
Session 6-6: Case Studies on Therapeutic MAbs for Inflammatory and Autoimmune Diseases
-Industrial and Clinical Symposium |
15:30-
17:10 |
Session 7-1: MAbs against Allergy GVHD, and Ischaemia |
Session 7-3: MAbs against Cardiovascular Diseases and Musculoskeletal Diseases
|
Session 7-5: MAbs against Age-related Macular Degeneration, Choroidal Neovascularisation (CNV) and Other Eye Diseases
|
Session 7-6: Case Studies on Therapeutic MAbs for Other Non-Cancer and Non-Infective Diseases
-Industrial and Clinical Symposium |
13:30-
15:10 |
Session 8-1: Novel Mab Target Discovery And Validations |
Session 8-3: Antibody Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety |
Session 8-5: Translating Engineered Antibodies from Bench to the Clinic |
15:30-
17:10 |
Session 9-1: Antigens, Polyclonal vs Monoclonal Antibodies, Biomarkers and Immunoassays |
Session 9-4: Antibodies for Diagnostics of Cardiovascular Diseases
|
Session 9-6: Antibody Directed Enzyme Prodrug Therapy (ADEPT) |
13:30-
14:40 |
Session 10-1: Cell Line and Model Organisms Development- Transgenic Animals, Transgenic Plants and High Yield Mammalian Cultures |
Session 10-3: Improved Purification Methodologies And Recovery Optimization
|
Session 10-5: Lyophilization Productivity and Bioanalytical Method Validation |
14:50-
16:10 |
Session 11-1: Pharmaceutical and patent law and Financing Strategies |
Session 11-3: Potentials of Outsourcing and Contract Manufacturing in Asia
|
Session 11-5: Effective Marketing Strategies and Distributions |
16:20-
17:40 |
Workshop 1: How to Publish Your Influential Discovery? |
Workshop 3: Regulatory Issues, IP and Social Acceptance
|
|
| Workshop 2: Mastering Combination mAb Therapies and Bispecific Antibodies |
Workshop 4: Understanding how to Manage Antibodies at Hospitals |
Home